GVHD remains a major source of morbidity and mortality after non-T cell-depleted BMT. The use of donor T lymphocytes expressing a suicide gene could lead to specific immunomodulation after BMT. We are currently evaluating such an approach in a phase I clinical study. A 12-day ex vivo expansion is required to generate gene-modified donor T lymphocytes. CsA is commonly used for GVHD prophylaxis. We analyzed, in a murine GVHD model, the effects of CsA administration on the alloreactivity of fresh or ex vivo-expanded T cells. Variable amounts of fresh or ex vivo-expanded T cells were administered in conjunction with a marrow graft to lethally irradiated allogeneic mice. As expected, a protective effect of CsA with a delayed GVHD-related mortality (P Ͻ 0.01 vs saline treatment) was observed in mice receiving fresh splenocytes. However, CsA treatment had no effect (P = NS) in mice experiencing lethal GVHD induced by ex vivo-expanded T cells whether or not the T cells had been 'rested' in low-dose IL-2 prior to in vivo administration. In agreement with the in vivo findings, CsA also inhibited the in vitro proliferation of alloreactive fresh T cells while having no significant inhibitory effect on the alloreactivity of ex vivoexpanded T lymphocytes. Overall, we demonstrate that the alloreactivity of ex vivo-expanded T lymphocytes is not sensitive to CsA and that this differential effect of CsA is not related to the alloreactive potential of the infused T cells. These findings could be highly relevant when considering allogeneic T cell therapy approaches.
specific ganciclovir (GCV)-induced in vivo T cell depletion if severe GVHD was to occur. 4 A phase I clinical study evaluating such an approach is underway in our institution. 5 The introduction of the HS-tk gene into donor T cells requires a 12 day ex vivo culture in the presence of IL-2 before infusion with donor hematopoietic stem cells. The 12 day transduction procedure includes a polyclonal (anti-CD3/IL-2) stimulation prior to retrovirus-mediated gene transfer (day 3) followed by a positive selection step (day 5 to 12). The gene-modified T cells are then infused to the patient in conjunction with the T cell-depleted bone marrow graft. Cyclosporin A (CsA) is a commonly used immunosuppressive agent in GVHD prophylaxis. 6, 7 CsA inhibits IL-2 synthesis, 8 which is one of the first events leading to the proliferation and differentiation of T lymphocytes.
The questions we addressed in this study were: does an in vivo CsA treatment for GVHD prophylaxis have comparable effects on the alloreactivity of fresh T lymphocytes vs ex vivo-expanded cells and, if not, what are the consequences of such a differential effect?
Materials and methods

Mice
Male 8-to 12-week-old BALB/c (H-2 d ) and C57BL/6 (B6, H-2 b ) were purchased from Iffa-Credo (L'Abresle, France). Transplanted mice were given sterile food and water supplemented with neomycin (Demavic, Longvic, France) at a final concentration of 2.5 mg/ml starting the day of BMT.
Cell culture
Spleen was used as a source of murine T cells. C57BL/6 mice were splenectomized, then a single cell suspension was obtained by serial passages through a 25-gauge needle. Spleen cells (SC) were grown for 12 days in RPMI 1640 supplemented with 25 mm Hepes, 2 mm l-glutamine, 100 Ul/ml penicillin, 100 g/ml streptomycin (Biowhittaker, Fontenay-sous-Bois, France), 5 ϫ 10 Ϫ5 m 2-mercaptoethanol (Sigma, Saint-Quentin Fallavier, France) and 10% fetal calf serum (DAP, Vogelgrun, France) at 37°C and 5% CO 2 . Concanavalin-A (2.5 g/ml) (Seromed, Berlin, Germany) and recombinant human IL-2 (500 Ul/ml) (Cetus, Rueil-Malmaison, France) were added to the culture media at the initiation of the culture. Recombinant human IL-2 was maintained at a final concentration of 500 Ul/ml in culture media throughout the 12-day culture period. For GVHD induction with cultured/rested T cells, cells were washed on day 12 and then cultured for an additional 48 h in the absence of IL-2.
Bone marrow transplantation
Bone marrow was flushed from donor (B6) tibiae and femora in RPMI 1640 with 25 mm Hepes supplemented with 2 mm l-glutamine, 100 g/ml streptomycin and 100 Ul/ml penicillin. After red blood cell lysis, pooled bone marrow (BM) and spleen cells (SC) were resuspended in PBS (Biowhittaker). Pathogen-free BALB/c mice were given a single lethal dose of total body irradiation (TBI, 8 Gy, 2.7 Gy/min). Twelve hours after TBI, mice were reconstituted with 1 ϫ 10 7 allogeneic bone marrow cells (BMC). For GVHD induction, mice were injected with an appropriate number of CD3 ϩ cells at the time of BMT. All cells were injected intravenously into a lateral tail vein.
CsA treatment
Starting 24 h prior to BMT, half of the recipients were treated with 50 mg/kg/day CsA (Sandimmune; Sandoz, Basel, Switzerland) diluted in PBS and the other half received PBS as a placebo. Injections were performed intraperitoneally 1/day in a volume of 0.3 ml per mouse.
GVHD evaluation
Clinical GVHD was monitored by mortality (daily) and body weight loss (weekly). GVHD was always confirmed by pathological analysis of target tissues (skin, gut, stomach).
Proliferation assay
Cultured and fresh cells were tested for their ability to proliferate in response to allogeneic stimulation or IL-2 (500 U/ml) with or without CsA at appropriate concentrations (see Results section). Cells were washed and cultured at a concentration of 5 ϫ 10 6 CD3 ϩ cells/ml in 96-well plates with or without CsA and stimulated with allogeneic cells 5 days before addition of 1 Ci of methyl- 
Cytokine production
Cultured and fresh cells were stimulated as described above. After 48 or 72 h culture, supernatant was harvested and centrifuged to avoid cellular contamination. IL-4 and IFN-␥ production was measured by an ELISA assay (Biotrak ELISA KIT; Amersham, Little Chalfont, UK).
Statistical analysis
Survival of transplanted mice was analyzed using the Kaplan-Meyer method and compared with Wilcoxon test.
Proliferation and cytokine production were compared with a Student's t-test.
Results
Effect of CsA on ex vivo-expanded T cell-mediated GVHD
The effect of CsA on GVHD occurrence was evaluated in a C57BL/6 into Balb/c BMT model. Fresh or ex vivoexpanded donor T cells were injected together with the BM graft in order to induce severe GVHD. PBS or CsA was administered daily until the end of the experiment. The administration of 1 ϫ 10 6 or 10 ϫ 10 6 fresh donor T cells led to a 100% GVHD-induced mortality in PBS-treated mice (day 25 and day 18, respectively). As expected, CsA administration had a protective effect in mice receiving fresh T lymphocytes since onset of GVHD was significantly delayed (P Ͻ 0.01) (Figure 1a and b) .
We have previously demonstrated that ex vivo-expanded T cells are also capable of strong in vivo alloreactivity. However, the administration of such cultured cells is associated with delayed GVHD occurrence when compared to fresh T lymphocytes. 9 Indeed, the administration of the same number of T cells (1 ϫ 10 6 or 10 ϫ 10 6 ) cultured for 12 days in vitro resulted in a lethal GVHD in mice occurring significantly later than with fresh T cells (Figure 1c and d). Importantly, in vivo CsA treatment did not delay the onset of GVHD (P = NS). To further examine if the observed absence of effect of CsA could be in relation to late occurrence of lethal GVHD, we examined the effect of CsA on the prophylaxis of lethal acute GVHD induced by a higher number of cultured T cells (3 ϫ 10 6 and 30 ϫ 10 6 ) and therefore occurring within the same period as with 1 ϫ 10 6 or 10 ϫ 10 6 fresh T cells. In this setting as well, CsA was unable to impact on the occurrence of cultured T cell-induced GVHD (Figure 2a and b) .
The CsA-resistance of expanded cell-mediated GVHD does not depend upon the proliferation rate or phenotype of expanded T cells
A short resting period of cultured T cells (48 h additional culture without IL-2) resulted in T cells that had a phenotype (a majority of CD4 ϩ cells vs CD8 ϩ cells prior to resting) and rate of dividing cells (1.7 Ϯ 0.3% T cells in S phase vs 25.5 Ϯ 1.3% prior to resting) similar to those of fresh T cells. 9 In addition, the reduced in vivo alloreactivity observed with the D12 cultured T cells was not observed with these cultured/rested T cells with the induction of lethal GVHD occurring within the same time period as with fresh T cells (Figure 3 vs 1) . However, as demonstrated in Figure 3a and b, CsA treatment did not have any protective effect on GVHD occurrence in mice receiving 1 ϫ 10 6 or 10 ϫ 10 6 CD3 ϩ cultured/rested T lymphocytes.
Effect of CsA on the in vitro alloreactivity of ex vivoexpanded T cells
Mixed lymphocyte reactions were performed in order to assess the effect of CsA on the in vitro alloreactivity of vs 14505 Ϯ 272 c.p.m.). The alloreactivity of fresh splenocytes was always inhibited by CsA at 10, 100 or 1000 ng/ml (33 Ϯ 5%, 96 Ϯ 2%, 95 Ϯ 1% growth inhibition respectively, P Ͻ 0.01) whereas the proliferation of ex vivo-expanded T lymphocytes following allogeneic stimulation was unaffected by CsA at 10 or 100 ng/ml (P = NS) and could be significantly decreased only at the highest dose CsA (1000 ng/ml and 10 000 ng/ml, P Ͻ 0.01) (Figure 4) . However, even at 1000 ng/ml CsA, cultured T cells remain more resistant than fresh splenocytes (66 Ϯ 9 vs 96 Ϯ 1% growth inhibition respectively, P Ͻ 0.05).
CsA-induced inhibition of IFN-␥ production
IL-4 and IFN-␥ levels were evaluated in supernatants of MLR after 48 or 72 h culture. IFN-␥ was not detectable in the absence of allogeneic stimulatory cells and its secretion in response to allogeneic stimulation was maximal at day 3 of MLR (data not shown). Interestingly, IFN-␥ levels were dramatically decreased by CsA exposure in culture supernatant of fresh splenocytes at a dose of 10 ng/ml (30 Ϯ 4% inhibition) and were undetectable at 100 and 1000 ng/ml. IFN-␥ production by ex vivo-expanded T lymphocytes was far more important than that observed with fresh cells and remained unaffected by CsA at 10 ng/ml (P = NS) and was still detectable at 100, 1000 and even 10 000 ng/ml CsA ( Figure 5 ). IL-4 was never detectable with or without CsA.
Discussion
While effectively preventing graft-versus-host disease (GVHD), T cell depletion is associated with increased graft rejection and relapse. 1 The ex vivo introduction of a gene encoding for a susceptibility factor ('suicide gene') into target cells leads to specific sensitivity to a chemotherapeutic agent, ordinarily not toxic, of such gene-modified cells. has been our contention that the use of such gene-modified donor T lymphocytes, in conjunction with an allogeneic T cell-depleted hematopoietic stem cell transplantation, could significantly increase the therapeutic value of bone marrow transplantation by allowing for a selective in vivo T cell depletion if significant graft-versus-host disease (GVHD) was to occur. 4 The preparation of gene-modified cells requires in our protocol a 12-day ex vivo expansion of donor T lymphocytes.
We demonstrate in the present study that such an ex vivo culture period generates cells resistant to CsA exposure. Indeed, administration of CsA did not delay the onset of GVHD when ex vivo IL-2-expanded donor T cells were used as GVHD-inducing cells, whereas onset of GVHD induced by fresh donor T cells was significantly delayed. 9 CsA is commonly used for GVHD prophylaxis and acts on naive T cells by preventing, at concentrations between 10 and 100 ng/ml, TCR-induced IL-2 synthesis, leading to an inhibition of T cell progression through the cell cycle in S phase. 8 However, because CsA does not interfere with IL-2 signaling, exogenous IL-2 can reverse the inhibition of T cell activation by low CsA doses. 11 The efficiency of CsA on activated cells depends on its concentration, the kind of stimuli, the T cell phenotype and the biological response evaluated: both TCR-induced cytokine production by CD4 ϩ and CD8 ϩ clones are inhibited by CsA. However, CsA inhibits TCR-induced, but not IL-2-induced, proliferation of CD4 ϩ T cell clones, but is ineffective on both TCR and IL-2-induced CD8 ϩ T cell clone proliferation. 12 Moreover, CsA prevents the acquisition of lytic potential by most CTL precursors but does not inhibit the cytotoxic activity of CD8 ϩ clones. 13 Thus, the inability of CsA to prevent ex vivo-expanded cell-induced GVHD may be related to the lower CD4/CD8 ratio observed in these cells than in fresh cells. However, this hypothesis is not compatible with the fact that GVHD induced by cultured/rested T cells remains resistant to a CsA treatment despite a CD4/CD8 ratio similar to fresh T cells.
Cyclosporin A enters the target cell via a membrane receptor and concentrates in the cytoplasm where it binds to a cis-trans prolyl isomerase, cyclophylin.
14 The CsA/cyclophylin complex interacts with the phosphatase calcineurin, thereby inhibiting its phosphatase activity. 15 This inhibition prevents the calcineurin-mediated dephosphorylation of the transcription factor NF-ATp into its activated form NF-AT and its subsequent nuclear translocation to the IL-2 gene promoter. 16, 17 CsA must be present within the first hours of T cell activation in order to exert its suppressive effects. 18 Thus, ex vivo IL-2-expanded cells may be CsA resistant because CsA is no longer effective if added once NF-AT has translocated to the nucleus.
In our model, the onset of GVHD and the preventive effects of CsA on its occurrence correlated with the proliferative response of alloreactive cells in mixed lymphocyte cultures (MLC). Indeed, the delayed onset of GVHD observed with activated cells was associated with a lower alloreactive proliferative response. Moreover, both onset of GVHD and proliferation in MLC were CsA-sensitive when fresh splenocytes were used as responding cells, whereas these parameters were CsA-resistant with activated responding T cells. This is in agreement with the observation that CsA prevents the development of GVHD, 6, 7, 19 but is less efficient in reversing established GVHD 20 (ie if administered when alloreactive cells are already activated).
In contrast to the in vitro proliferative response, spontaneous or alloantigen-induced IFN-␥ production did not correlate with the alloreactive potential of infused cells. Indeed, ex vivo-expanded cells produced far more IFN-␥ on a per cell basis, despite being less efficient in inducing a GVHD, than fresh cells. As observed for proliferative responses in MLC, in vitro IFN-␥ production by resting cells was completely inhibited by CsA concentrations similar to in vivo circulating CsA levels (10-100 ng/ml), whereas IFN-␥ secretion by activated cells was only partially reduced. At higher CsA concentrations (1000 ng/ml), IFN-␥ levels produced by cultured T cells, although being 90% inhibited, remained more important than those observed with fresh cells that were stimulated in the absence of CsA.
The role of IFN-␥ in the physiopathology of GVHD and in the MLC proliferative response remains controversial. In the 'cytokine storm' model suggested by Ferrara et al 21 IFN-␥ plays a major role both in the afferent and efferent phases of acute GVHD. Indeed, IFN-␥ production has been reported during GVHD 22 and IFN-␥ has been detected within GVHD lesions. 23 However, studies reporting the effects of the systemic administration of IFN-␥ or anti-IFN-␥ monoclonal antibodies (mAbs) on GVHD gave contrasting results. Although IFN-␥-specific mAbs prevent GVHD induction, 24, 25 IFN-␥ administration has also been shown to reduce GVHD occurrence and its associated mortality. 25, 26 Similarly, in vitro studies aimed at analyzing the role of IFN-␥ during MLC responses have shown that anti-IFN-␥ mAbs can enhance or inhibit proliferative responses in MLC. It has been proposed that locally produced IFN-␥ would be involved in GVHD induction, whereas systemically administered IFN-␥ may inhibit its occurrence through a negative feed-back loop. 25 In our model, resting cells do not secrete IFN-␥ spontaneously, whereas activated cells produce significant amounts of IFN-␥ even after 3 days culture without stimuli (data not shown). Thus, we hypothesize that when injected to recipient mice, activated cells may produce high levels of systemic, inhibitory IFN-␥ immediately (and even higher levels when alloreactive cells are later stimulated), whereas among administered fresh cells, only the alloreactive subpopulation would secrete IFN-␥ locally, in a delayed manner, leading to immune stimulation and GVHD promotion. In the presence of CsA, alloantigen-induced IFN-␥ production by fresh cells would be inhibited, thus preventing GVHD induction. By contrast, even with high CsA doses, IFN-␥ secretion by alloreactive ex vivo-expanded cells would be partially inhibited and remaining systemic IFN-␥ levels would be sufficient to exert their inhibitory properties.
The observation in the present report that CsA does not prevent the development of GVHD induced by ex vivoexpanded T cells is of clinical relevance. In our on-going clinical trial involving the use of HS-tk-expressing donor T cells, CsA treatment might reduce the alloreactive potential of the residual 'fresh' donor T cells infused with the T cell-depleted marrow graft while having no effect on the alloreactivity of the co-administered GCV-sensitive genemodified donor T cells. These findings could be highly relevant for the use of suicide gene-expressing donor T cells 5, 27 or other allogeneic T cell-based approaches 28 after allogeneic HSC transplantation.
